Avidity Biosciences

65 articles with Avidity Biosciences

• Lilly and Avidity Biosciences Announce Licensing and Research Collaboration

  4/22/2019

  Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties

• 

  Eli Lilly and Avidity Forge Agreement for Immunologic Candidates

  4/22/2019

  The two companies will combine their expertise to drive new immunology candidates toward the clinic.

• Avidity Biosciences' Arthur A. Levin Publishes Review of Therapeutic Approaches of Targeting RNA in the New England Journal of Medicine

  1/3/2019

  Arthur A. Levin, Ph.D, executive vice president of research and development at Avidity Biosciences LLC, a biotechnology company advancing Antibody- Oligonucleotide Conjugates (AOCs) as a new class of precision medicines, today published a review titled, "Treating Disease at the RNA Level with Oligonucleotides" in the January 3, 2018, issue of the New England Journal of Medicine1.

• Avidity Biosciences Receives Investment from CureDuchenne

  10/17/2018

  Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy

• Avidity Biosciences Raises $16 Million In Series B Financing To Advance Antibody-Sirna Conjugate Platform

  1/5/2017